Phase 2 Start
TELO: Phase 2 Start: A First-in-Human (FIH), Phase I/II, Multicenter, Open-Label Study to Evaluate the Safety, Tolerabili
October 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 1, 2026
- Company
- Telomir Pharmaceuticals, Inc. (TELO)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A First-in-Human (FIH), Phase I/II, Multicenter, Open-Label Study to Evaluate the Safety, Tolerabili
- Indication
- Metastatic Triple-negative Breast Cancer; Triple-Negative Breast Cancer (TNBC); Advanced Triple-Negative Breast Cancer